University of Queensland Centre for Clinical Research, Royal Brisbane and Woman's Hospital, Herston, Queensland, 4029, Australia.
Department of Infectious Diseases, Mater Hospital Brisbane, South Brisbane, Queensland, 4101, Australia.
Future Microbiol. 2021 Mar;16:271-288. doi: 10.2217/fmb-2020-0202. Epub 2021 Feb 17.
Melioidosis is an emerging infectious disease with an estimated global burden of 4.64 million disability-adjusted life years per year. A major determinant related to poor disease outcomes is delay to diagnosis due to the fact that identification of the causative agent may be challenging. Over the last 25 years, advances in molecular diagnostic techniques have resulted in the potential for rapid and accurate organism detection and identification direct from clinical samples. While these methods are not yet routine in clinical practice, laboratory diagnosis of infectious diseases is transitioning to culture-independent techniques. This review article aims to evaluate molecular methods for melioidosis diagnosis direct from clinical samples and discuss current and future utility and limitations.
类鼻疽病是一种新出现的传染病，据估计，每年全球有 464 万人因此丧失伤残调整生命年。由于确定病原体可能具有挑战性，导致诊断延迟，这是与不良疾病结局相关的一个主要决定因素。在过去的 25 年中，分子诊断技术的进步使得直接从临床样本中快速准确地检测和鉴定病原体成为可能。虽然这些方法在临床实践中尚未常规应用，但传染病的实验室诊断正在向非培养技术转变。本文旨在评估直接从临床样本中诊断类鼻疽病的分子方法，并讨论其当前和未来的实用性和局限性。
